Eli Lilly and Company today announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor degrader (SERD), olomorasib, an investigational KRAS G12C inhibitor, ...

Clinicians and scientists from RWJBarnabas Health and Rutgers Cancer Institute will share new findings and lead discussions ...